Theravance Biopharma (NASDAQ:TBPH) Downgraded to Hold at StockNews.com

StockNews.com lowered shares of Theravance Biopharma (NASDAQ:TBPHGet Rating) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

Other research analysts also recently issued research reports about the stock. HC Wainwright raised their price target on shares of Theravance Biopharma from $12.00 to $19.00 and gave the company a buy rating in a report on Tuesday, November 8th. SVB Leerink raised their price target on shares of Theravance Biopharma from $12.00 to $14.00 and gave the stock an outperform rating in a research report on Thursday, November 17th.

Theravance Biopharma Trading Up 0.8 %

Shares of NASDAQ:TBPH opened at $10.99 on Tuesday. The firm’s 50 day moving average is $10.92 and its two-hundred day moving average is $10.09. The firm has a market capitalization of $740.35 million, a P/E ratio of 0.98 and a beta of 0.51. Theravance Biopharma has a 52 week low of $7.53 and a 52 week high of $11.83.

Theravance Biopharma (NASDAQ:TBPHGet Rating) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $12.45 million for the quarter, compared to the consensus estimate of $19.09 million. Analysts predict that Theravance Biopharma will post -0.88 EPS for the current year.

Insider Activity at Theravance Biopharma

In other news, CEO Rick E. Winningham sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 14th. The shares were sold at an average price of $11.19, for a total value of $559,500.00. Following the completion of the transaction, the chief executive officer now owns 1,350,797 shares in the company, valued at $15,115,418.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. UBS Group AG increased its holdings in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,101 shares during the last quarter. Royal Bank of Canada grew its stake in Theravance Biopharma by 1,330.7% during the third quarter. Royal Bank of Canada now owns 6,610 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 6,148 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Theravance Biopharma during the second quarter worth about $62,000. Acadian Asset Management LLC lifted its holdings in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,818 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Theravance Biopharma by 292.4% in the third quarter. Tower Research Capital LLC TRC now owns 9,877 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 7,360 shares during the last quarter.

Theravance Biopharma Company Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Further Reading

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.